Welcome to our dedicated page for Smith & Nephew SEC filings (Ticker: SNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Smith & Nephew plc (SNN) regulatory disclosures filed with the U.S. Securities and Exchange Commission, primarily through Form 6-K current reports for foreign private issuers. These filings give investors structured insight into the company’s capital structure, strategy, acquisitions and transactions by senior management.
Smith & Nephew uses Form 6-K to report a range of information, including announcements about its RISE strategy and related 2028 financial targets for revenue growth, trading profit, free cash flow and post-tax return on invested capital. Other 6-Ks detail portfolio rationalisation plans, guidance for upcoming financial years, and information on Capital Markets Day events where management presents strategic and product updates.
Filings also include voting rights and capital disclosures, setting out the total issued share capital, treasury shares and the number of voting rights that shareholders should use when assessing notification thresholds under applicable transparency rules. Separate TR-1 notifications, reproduced within 6-Ks, report major holdings changes by institutional investors such as BlackRock, Inc., including the percentage of voting rights attached to shares and through financial instruments.
Additional 6-K reports provide Market Abuse Regulation-compliant notifications of transactions by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These cover purchases of ordinary shares and American Depositary Shares, participation in dividend reinvestment and employee stock purchase plans, and vesting of restricted share awards, giving a view of insider dealing activity around SNN securities.
Investors can also find transaction-related disclosures, such as the acquisition of Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology, including headline deal terms, strategic rationale within the Sports Medicine portfolio and comments from management. By combining real-time EDGAR updates with AI-powered summaries, this page helps users navigate Smith & Nephew’s 6-Ks, understand the implications of voting rights and insider transactions, and quickly grasp the strategic content of narrative announcements without reading every paragraph in full.
Smith & Nephew plc reported that senior executives received new share awards under its RISE Share Plan. On 15 April 2026, the company granted awards over ordinary shares of US$0.20 each to multiple persons discharging managerial responsibilities, including the Chief Executive Officer and Chief Financial Officer, with each listed executive allocated 50 shares at nil cost. The awards form part of the company’s RISE strategy and were granted under the Smith & Nephew plc RISE Share Plan, a sub-plan of the Smith & Nephew plc Restricted Share Plan 2024.
Smith & Nephew plc filed a report noting that Thérèse Esperdy, its Senior Independent Director designate, will join the Board of Rentokil Initial plc as a Non-Executive Director and Chair-designate from 1 July 2026, becoming Chair of the Board on 1 September 2026. The company also highlights that it operates in more than 100 countries with $6.2 billion in annual sales in 2025, supported by around 17,000 employees across its orthopaedics, sports medicine & ENT, and advanced wound management businesses.
Smith & Nephew plc submitted an amended report to clarify how investors can access its 2025 Annual Report, 2026 AGM materials, and proposed new Articles of Association. The company confirms these documents are on the UK National Storage Mechanism and its website, and that hard copies are available free of charge to shareholders and ADS holders upon request to the Company Secretariat in Watford, England.
Smith & Nephew plc reports new share-based awards for senior leaders under three incentive plans. On 1 April 2026, the CEO and CFO deferred 50% of their 2025 annual bonuses into share awards under the Deferred Share Bonus Plan, using a price of £12.744 per share, with vesting scheduled for 15 March 2029.
Additional performance share awards were granted under the Global Share Plan 2020, also at £12.744 per share, with vesting in 2029 subject to performance measured from 1 January 2026 to 31 December 2028. Further time-based awards were made under the Restricted Share Plan 2024, vesting in equal annual tranches over three years, with the CEO and CFO awards subject to a judgement-based underpin linked to financial, regulatory, ESG, safety and reputational outcomes.
Smith & Nephew plc reports its updated share capital and voting rights position. As at 31 March 2026, the company has 877,733,750 ordinary shares of US20¢ each in issue, including 23,761,952 held in treasury. The issued share capital with voting rights consists of 853,971,798 ordinary shares, each carrying one vote. Shareholders are directed to use 853,971,798 as the denominator when assessing whether they must notify holdings or changes under the FCA’s Disclosure Guidance and Transparency Rules.
Smith & Nephew plc reported that on 23 March 2026 multiple executive and senior managers had share awards vest under its Global Share Plans 2010/2020 and Restricted Share Plan 2024.
Ordinary shares were delivered and portions sold on the London Stock Exchange at £11.938637 to cover tax liabilities, with the balance retained by each participant.
Smith & Nephew reports that funds controlled by Cevian Capital II G.P. Limited now hold 10.094356% of its voting rights, equal to 85,790,848 voting rights. This more than doubles their previously notified position of 5.021046%. The stake is held legally by Aurora Nominees Limited on behalf of UBS AG as custodian.
Cevian Capital II GP LTD filed Amendment No. 4 to its Schedule 13D on Smith & Nephew plc, reporting beneficial ownership of 81,687,136 ordinary shares, equal to 9.6% of the outstanding shares. Cevian has sole voting and dispositive power over this entire stake.
Cevian states it bought these shares for the Cevian funds for total consideration of about USD $1,095,708,998, funding the purchases from the funds’ general working capital and paying in British pounds, using an exchange rate of USD $1.32385 per GBP 1.00. The 9.6% figure is based on 849,889,305 ordinary shares outstanding as of February 28, 2026, as reported by the issuer on Form 6-K filed on March 2, 2026.
Smith & Nephew plc submitted a Form 6-K to inform investors that its 2025 Annual Report and related shareholder documents are now available. The company has published the 2025 Annual Report, the Notice of the 2026 Annual General Meeting, the Form of Proxy for the 2026 AGM, and proposed new Articles of Association.
The 2025 Annual Report on Form 20-F was also filed with the SEC on the same day, and all documents are accessible via the UK National Storage Mechanism and the company’s investor relations website.
Smith & Nephew plc filed a Form 6-K stating that it has sent its annual report for fiscal year 2025 to shareholders. The report for the year ended 31 December 2025 is attached as Exhibit 99.1. This filing is primarily administrative, forwarding the full annual report to investors.